Greenlee RT, Kessel B, Williams CR, et al. Prevalence, incidence, and natural history of simple ovarian cysts among women >55 years old in a large cancer screening trial. Am J Obstet Gynecol 2010;202:373e1–e9.
265.
Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 2003;102:594–599.
266.
ACOG Committee Opinion No. 280. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002;100:1413–1416.
267.
Lynch PJ, Moyal-Barracco M, Bogliatto F, et al. 2006 ISSVD classification of vulvar dermatoses: pathologic subsets and their clinical correlates. J Reprod Med 2007;52:3–9.
268.
Maclean AB, Jones RW, Scurry J, et al. Vulvar cancer and the need for awareness of precursor lesions. J Low Genit Tract Dis 2009;13:115–117.
269.
Ayhan A, Guven ES, Guven S, et al. Testosterone versus clobetasol for maintenance of vulvar lichen sclerosus associated with variable degrees of squamous cell hyperplasia. Acta Obstet Gynecol Scand 2007;86:715–719.
270.
Sinha P, Sorinola O, Luesley DM. Lichen sclerosus of the vulva. Long-term steroid maintenance therapy. J Reprod Med 1999;44:621– 624.
271.
Bradford J, Fischer G. Long-term management of vulval lichen sclerosus in adult women. Aust N Z J Obstet Gynaecol 2010;50:148– 152.
272.
Yesudian PD. The role of calcineurin inhibitors in the management of lichen sclerosus. Am J Clin Dermatol 2009;10:313–318.
273.
Sideri M, Jones RW, Wilkinson EJ, et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med 2005;50:807–810.
274.
Ballagh SA. Vaginal hormone therapy for urogenital and menopausal symptoms. Semin Reprod Med 2005;23:126–140.
275.
Palacios S. Managing urogenital atrophy. Maturitas 2009;63:315– 318.
William H. Parker
Fibroids are very common and most are asymptomatic and can be managed expectantly.
There is no definite relationship between oral contraceptives and the presence of fibroids.
First-degree relatives of women with fibroids have a 2.5 times increased risk of developing fibroids.
The risk of having fibroids is 2.9 times greater in African American women than in white women.
Women with fibroids are only slightly more likely to experience pelvic pain than women without fibroids.
Rapid uterine growth is not well defined, and almost never indicates sarcoma in premenopausal women; sarcomas are rare and more likely occur in postmenopausal women with symptoms of pain and bleeding.